Canadian Population Serological Survey Utilizing Antenatal Serum Samples

The objectives of the Canadian Population Serological Survey Utilizing Antenatal Serum Samples are to: * Provide an immediate cross-sectional assessment of the seroprevalence of antibodies to SARS-CoV-2 in Canada. * Assess the retrospective evolution of SARS-CoV-2 prevalence; antenatal serology can be assessed going back one year thereby providing an opportunity to go back to where 0% prevalence is detected. * Plan to perform periodic future seroprevalence based on the level of seroprevalence on the first cross-sectional assessment. * Compare seroprevalence between Canadian provinces and territories.

Overview

Acronym
CPSS-Antenatal
Investigators
Dr. Deborah Money
FRCSC (University of British Columbia)
Contacts
Janice Andrade
University of British Columbia

General Design

Study design
Cross-sectional
Start - End Year
2020 - 2021
General Information on Follow Up (profile, frequency)
Periodic assessment of seroprevalence of SARS-CoV-2 utilizing clinically collected prenatal serology samples may be planned for future time points. The frequency and number of samples will be determined based on findings from the first cross-sectional assessment.
Recruitment Target
  • Individuals
Number of Participants
18,000
Supplementary information about number of participants
Cohort 1: 18,000 participants

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Populations

CPSS-Antenatal - Cohort 1
The population is composed of pregnant women in all provinces and territories of Canada who have their prenatal serology results available in laboratories.

Selection Criteria

Sex
Women only
Pregnant Women
  • First trimester
Countries
  • Canada
Canadian Provinces
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland and Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Other Criteria
Had a routine blood screening of the antibody status to rubella, HIV, Hepatits B and syphilis

Sources of Recruitment

Specific Population
  • Clinic patients
Supplementary Information
Pregnant women who get a routine blood screening for prenatal care and who have their serological test results available for testing.

Sample Size

Number of Participants
18,000
Number of Participants with Biological Samples
18,000

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 CPSS-Antenatal - Cohort 1 - Serotest
  • Biosamples
  • Administrative databases
  • Blood
2020 (November) 2021 (March)
CPSS-Antenatal - Cohort 2
The population is composed of pregnant women in all provinces and territories of Canada who have their antenatal screening for aneuploidy results available in laboratories.

Selection Criteria

Sex
Women only
Pregnant Women
  • First trimester
  • Second trimester
Countries
  • Canada
Canadian Provinces
  • Alberta
  • British Columbia
  • Manitoba
  • New Brunswick
  • Newfoundland and Labrador
  • Northwest Territories
  • Nova Scotia
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Other Criteria
Had an aneuploidy blood screening

Sources of Recruitment

Specific Population
  • Clinic patients
Supplementary Information
Pregnant women who get a routine blood screening for prenatal care and who have their aneuploidy test results data available for testing.

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 CPSS-Antenatal - Cohort 2 - Retrospective survey
  • Biosamples
  • Administrative databases
  • Blood
2019 (December) 2020 (December)

Participating Studies

Acronym Name Study design Countries

Harmonization Initiatives Included

Acronym Name

Datasets

Name Data Collection Events Variables

Areas of Information Collected

Socio-demographic and economic characteristics
Death
Lifestyle and behaviours
Physical measures and assessments
Birth, pregnancy and reproductive health history
Laboratory measures
Perception of health, quality of life, development and functional limitations
Cognition, personality and psychological measures and assessments
Diseases
Life events, life plans, beliefs and values
Symptoms and signs
Preschool, school and work life
Medication and supplements
Social environment and relationships
Non-pharmacological interventions
Physical environment
Health and community care services utilization
Administrative information

Variables Content Summary

Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected

Networks

Acronym Name Harmonization Initiatives Individual Studies
Last Update: 2024-02-27T12:09:39.733